CMS (00867): Innovative Oral Small Molecule JAK1 Inhibitor Povorcitinib Receives Clinical Trial Approval for Vitiligo and Hidradenitis Suppurativa Indications

Stock News

Aug 28

CMS (00867) announced that its subsidiary DeMai Pharmaceuticals Limited (DeMai Pharmaceuticals, an innovative pharmaceutical company focused on dermatological health that is applying for independent listing on the Main Board of The Stock Exchange of Hong Kong Limited) together with its subsidiaries received a Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration (NMPA) on August 27, 2025, with the notice received on August 28, 2025.

The NMPA has approved the conduct of clinical trials for povorcitinib (proposed Chinese generic name: Povorcitinib Phosphate Tablets) for the treatment of non-segmental vitiligo and moderate-to-severe hidradenitis suppurativa (HS).

Povorcitinib is a selective oral small molecule JAK1 inhibitor with substance and use patents in specific countries/regions. Currently, povorcitinib is undergoing Phase 3 clinical trials in several overseas countries for non-segmental vitiligo, HS, and nodular prurigo. Additionally, Phase 2 clinical trials for the treatment of asthma and chronic spontaneous urticaria are also in progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1100103646"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100103646\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100103646?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100103646","market":"nz","top_or_hot":-1,"title":"CMS (00867): Innovative Oral Small Molecule JAK1 Inhibitor Povorcitinib Receives Clinical Trial Approval for Vitiligo and Hidradenitis Suppurativa Indications","media":"Stock News","content":"<p>CMS (00867) announced that its subsidiary DeMai Pharmaceuticals Limited (DeMai Pharmaceuticals, an innovative pharmaceutical company focused on dermatological health that is applying for independent listing on the Main Board of The Stock Exchange of Hong Kong Limited) together with its subsidiaries received a Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration (NMPA) on August 27, 2025, with the notice received on August 28, 2025.</p>\n<p>The NMPA has approved the conduct of clinical trials for povorcitinib (proposed Chinese generic name: Povorcitinib Phosphate Tablets) for the treatment of non-segmental vitiligo and moderate-to-severe hidradenitis suppurativa (HS).</p>\n<p>Povorcitinib is a selective oral small molecule JAK1 inhibitor with substance and use patents in specific countries/regions. Currently, povorcitinib is undergoing Phase 3 clinical trials in several overseas countries for non-segmental vitiligo, HS, and nodular prurigo. Additionally, Phase 2 clinical trials for the treatment of asthma and chronic spontaneous urticaria are also in progress.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMS (00867): Innovative Oral Small Molecule JAK1 Inhibitor Povorcitinib Receives Clinical Trial Approval for Vitiligo and Hidradenitis Suppurativa Indications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMS (00867): Innovative Oral Small Molecule JAK1 Inhibitor Povorcitinib Receives Clinical Trial Approval for Vitiligo and Hidradenitis Suppurativa Indications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-28 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CMS (00867) announced that its subsidiary DeMai Pharmaceuticals Limited (DeMai Pharmaceuticals, an innovative pharmaceutical company focused on dermatological health that is applying for independent listing on the Main Board of The Stock Exchange of Hong Kong Limited) together with its subsidiaries received a Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration (NMPA) on August 27, 2025, with the notice received on August 28, 2025.</p>\n<p>The NMPA has approved the conduct of clinical trials for povorcitinib (proposed Chinese generic name: Povorcitinib Phosphate Tablets) for the treatment of non-segmental vitiligo and moderate-to-severe hidradenitis suppurativa (HS).</p>\n<p>Povorcitinib is a selective oral small molecule JAK1 inhibitor with substance and use patents in specific countries/regions. Currently, povorcitinib is undergoing Phase 3 clinical trials in several overseas countries for non-segmental vitiligo, HS, and nodular prurigo. Additionally, Phase 2 clinical trials for the treatment of asthma and chronic spontaneous urticaria are also in progress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BVYPNP33.GBP","symbol_name":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","start_time":0,"source_url":"","article_id":"1100103646","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100103646","pubTimestamp":1756384997,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CMS (00867) announced that its subsidiary DeMai Pharmaceuticals Limited (DeMai Pharmaceuticals, an innovative pharmaceutical company focused on dermatological health that is applying for independent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","06978":"永泰生物-B","SG9999015978.USD":"利安颠覆性创新基金A","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","BK1191":"制药","BK1161":"生物科技","BK1593":"医美概念股","00867":"康哲药业","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","BK1574":"生物医药B类股","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD"},"translate_title":"CMS(00867)：创新口服小分子JAK1抑制剂Povorcitinib获白癜风及化脓性汗腺炎适应症临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"00867":1,"06978":1},"content_text":"CMS (00867) announced that its subsidiary DeMai Pharmaceuticals Limited (DeMai Pharmaceuticals, an innovative pharmaceutical company focused on dermatological health that is applying for independent listing on the Main Board of The Stock Exchange of Hong Kong Limited) together with its subsidiaries received a Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration (NMPA) on August 27, 2025, with the notice received on August 28, 2025.\nThe NMPA has approved the conduct of clinical trials for povorcitinib (proposed Chinese generic name: Povorcitinib Phosphate Tablets) for the treatment of non-segmental vitiligo and moderate-to-severe hidradenitis suppurativa (HS).\nPovorcitinib is a selective oral small molecule JAK1 inhibitor with substance and use patents in specific countries/regions. Currently, povorcitinib is undergoing Phase 3 clinical trials in several overseas countries for non-segmental vitiligo, HS, and nodular prurigo. Additionally, Phase 2 clinical trials for the treatment of asthma and chronic spontaneous urticaria are also in progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}